PT  - JOURNAL ARTICLE
AU  - Watson, Caroline M.
AU  - Dammer, Eric B.
AU  - Ping, Lingyan
AU  - Duong, Duc M.
AU  - Modeste, Erica
AU  - Carter, E. Kathleen
AU  - Johnson, Erik C. B.
AU  - Levey, Allan I.
AU  - Lah, James J.
AU  - Roberts, Blaine R.
AU  - Seyfried, Nicholas T.
TI  - Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease
AID  - 10.1101/2022.08.30.22279370
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.08.30.22279370
4099  - http://medrxiv.org/content/early/2023/01/23/2022.08.30.22279370.short
4100  - http://medrxiv.org/content/early/2023/01/23/2022.08.30.22279370.full
AB  - Alzheimer’s disease (AD) is the most common form of dementia, with cerebrospinal fluid (CSF) β-amyloid (Aβ), total Tau, and phosphorylated Tau providing the most sensitive and specific biomarkers for diagnosis. However, these diagnostic biomarkers do not reflect the complex changes in AD brain beyond amyloid (A) and Tau (T) pathologies. Here, we report a selected reaction monitoring mass spectrometry (SRM-MS) method with isotopically labeled standards for relative protein quantification in CSF. Biomarker positive (AT+) and negative (AT-) CSF pools were used as quality controls (QCs) to assess assay precision. We detected 62 peptides (51 proteins) with an average CV of ∼13% across 30 QCs and 133 controls (cognitively normal, AT), 127 asymptomatic (cognitively normal, AT+) and 130 symptomatic AD (cognitively impaired, AT+). Proteins that could distinguish AT+ from AT-individuals included SMOC1, GDA, 14-3-3 proteins, and those involved in glycolysis. Proteins that could distinguish cognitive impairment were mainly neuronal proteins (VGF, NPTX2, NPTXR, and SCG2). This demonstrates the utility of SRM-MS to quantify CSF protein biomarkers across stages of AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the following National Institutes of Health funding mechanisms: U01AG061357 (A.I.L and N.T.S), R01AG070937-01 (J.J.L) and P30AG066511 (A.I.L).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board (IRB) at Emory University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw mass spectrometry and pre- and post- processed peptide abundance data can be found at https://www.synapse.org/#!Synapse:syn34054965. The results published here are in whole or in part based on data obtained from the AMP-AD Knowledge Portal (https://adknowledgeportal.synapse.org) by the AMP-AD Target Discovery Program and other programs supported by the National Institute on Aging to enable open-science practices and accelerate translational learning. https://www.synapse.org/#!Synapse:syn34054965